摘要
目的探讨雷贝拉唑、兰索拉唑及奥美拉唑三联疗法治疗幽门螺杆菌(Hp)感染消化性胃溃疡临床疗效及安全性,为临床治疗Hp感染消化性胃溃疡提供参考。方法选择2010年3月-2014年6月医院收治的128例Hp感染性胃溃疡患者为研究对象,将患者随机分为A组42例、B组43例与C组43例,A组患者给予奥美拉唑+阿莫西林+克拉霉素,B组患者给予兰索拉唑+阿莫西林+克拉霉素,C组患者给予雷贝拉唑+阿莫西林+克拉霉素,连续治疗4周,评价患者症状改善及治疗后溃疡愈合及Hp根除情况。结果治疗后总有效率A组为76.19%、B组为74.42%、C组为81.39%,3组比较差异无统计学意义;3组Hp根除率比较差异无统计学意义;3组临床症状与胃溃疡面直径均显著减少(P<0.05);3组IL-6、IL-8水平均显著低于治疗前(P<0.05);治疗后IL-6、IL-8水平3组比较均无显著差异;不良反应发生率A组为9.52%、B组为11.63%、C组为6.98%,3组比较差异无统计学意义。结论雷贝拉唑、兰索拉唑及奥美拉唑三联疗法均可根除Hp,促进胃溃疡愈合,缓解消化性胃溃疡临床症状,雷贝拉唑三联疗法在促进胃溃疡愈合及改善临床症状优于兰索拉唑及奥美拉唑。
OBJECTIVE To explore the clinical efficacies and safety of the triple therapy of rabeprazole,lansoprazole and omeprazole in treatment of peptic gastric ulcers associated with Helicobacter pylori infection so as to provide guidance for clinical treatment of the peptic gastric ulcers associated with H.pyloriinfection.METHODS A total of128 patients with H.pylori infection-associated gastric ulcers who were treated from Mar 2010 to Jun 2014 were recruited as the study objects and randomly divided into the group A with 42 cases,the group B with 43 cases,and the group C with 43 cases.The group A was treated with omeprazole plus amoxacillin plus clindamycin,the group B was treated with lansoprazole plus amoxacillin plus clindamycin,and the group C was treated with rabeprazole plus amoxacillin and clindamycin for 4consecutive weeks.The improvement of symptoms,ulcers healing,and eradication of H.pylori were evaluated.RESULTS The total effective rate of treatment was 76.19% in the group A,74.42%in the group B,81.39%in the group C,and there was no significance among the three groups.There was no significant difference in the eradication rate of H.pylori among the three groups.The clinical symptoms and the diameters of ulcers surfaces of the three groups were significantly reduced（P〈0.05）.The levels of IL-6and IL-8of the three groups were significantly lower after the treatment than before the treatment（P〈0.05）;there was no significant difference in the level of IL-6or IL-8among the three groups after the treatment.The incidence of adverse reactions was 9.52% in the group A,11.63% in the group B,and 6.98% in the group C.CONCLUSIONThe triple therapy of rabeprazole,lansoprazole and omeprazole can eradicate the H.pylori,facilitate the healing of gastric ulcers,and relieve the clinical symptoms of the peptic gastric ulcer.The triple therapy of rabeprazole is superior to the triple therapy of lansoprazole or omeprazole in facilitating the healing of gastric ulcers and improving the clinical symptoms.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2015年第18期4183-4185,共3页
Chinese Journal of Nosocomiology
基金
国家自然科学基金杰出青年基金资助项目(30225039)
